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The current volume is indeed directed to clinicians and their 
everyday clinical work. It covers several psychopharmaco-
logical issues of great clinical relevance: therapy resistance, 
chronicity, side effects. All three of them belong to the gen-
eral topic of difficult-to-treat patients. In this editorial, I will 
focus on those papers which focus on therapy resistance/
chronicity.
In this context, the French population-based study (Panes 
et al.) on the use of Benzodiazepines is of great impor-
tance. She comes to the conclusion that the Benzodiazepine 
use was not in accordance with international and French 
guidelines in 30% of new hypnotic users and 20% of new 
anxiolytic users. Benzodiazepine use not in accordance with 
guidelines was defined by the authors as the concomitant 
dispensation of several benzodiazepines, the dispensation of 
benzodiazepine treatment over a longer period than recom-
mended (in most guidelines no longer than 4 weeks), consid-
ering that the French recommendations distinguish between 
the time limitation for hypnotic (4 weeks) and anxiolytic 
benzodiazepines (12 weeks), and a new dispensing within 
the 2 months following the end of previous treatment of 
maximum recommended duration. Associated characteris-
tics of non-compliance with the guideline recommendations 
were older age, treatment initiation by a psychiatrist, the 
presence of chronic disease, hospitalisation or another psy-
chotropic treatment. All these background factors demon-
strate that these are not the average patients of practitioners, 
but apparently difficult-to-treat patients.
This result is not unexpected and fits to the experience 
in other European countries and worldwide. Does this indi-
cate an un-reflected prescription pattern of the doctors or 
a low-dose dependency in a large subgroup of patients or 
does it mirror the need of patients suffering from chronic 
sleep and anxiety disorders. The apparent need for long-
term medication, which is the message of the data, and the 
respective background factors might be seen as consequence 
of the problem that the other indicated medications, such as 
e.g., the SSRIs for the treatment of anxiety disorders, are in 
many cases, not sufficiently efficacious [1]. Similarly, sleep 
disturbances as well as anxiety treated with benzodiazepines 
might be a consequence of other psychic disorders, for which 
the specific medication such as antidepressants or antip-
sychotics is not sufficient enough to reduce all respective 
symptoms [2–4]. Doctors or patients in such situations might 
look for other solutions, although they are unspecific for 
the respective disorder. Also, the special problem of mixed 
anxiety depression should be considered in this context [5].
The paper (Panes et al.) on Clozapin gives some further 
hints into problem of therapy resistance. The chart review 
on long-term treatment with Clozapin reports important 
aspects of therapy resistance/chronicity in schizophrenia 
and the related response/nonresponse trajectories 40–70% 
of patients on Clozapine have persistent psychotic symptoms 
(ultra-treatment resistant schizophrenia, UTRS). Of those 
patients who were diagnosed UTRS after about 10 months 
(mean duration) of treatment with Clozapine 87% remained 
unresponsive after about 7 years (mean duration), only 13% 
became responsive. Thus, even with Clozapine, which has 
the indication for treatment-resistant schizophrenia, we are 
faced with the problem that a large subgroup of patients is 
so treatment resistant that Clozapine as monotherapy is not 
sufficient efficacious to overcome the problem. Combination 
strategies or even better new medications are necessary. But 
there is only weak evidence for combination strategies and 
unfortunately, a new powerful antipsychotic for these cases 
is not on the horizon.
As mentioned before, combination treatment with antip-
sychotics needs further evaluation. Thus, the paper (Schmid-
Kraepelin et al.), describing the design of a three-arm RCT 
comparing the combination of Olanzapine with Amisul-
pride vs. each compound as monotherapy, goes in the right 
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direction. However, the study does not focus on treatment-
resistant patients, but on acutely ill schizophrenia patients.
Treatment resistance can be induced by different risk fac-
tors. Among others, pharmacokinetic may play a relevant 
role [6] and thus pharmacokinetic studies are needed. In 
this context, the study (Kiss et al.) on the phenoconversion 
of CYP2D6 by inhibitors and how this modifies aripiprazole 
exposure is of great interest.
It is well known that treatment resistance is a huge prob-
lem in the treatment of depression [2], on an average, 30% 
of patients do not achieve response and 50% no remission. 
For decades, the only solutions to overcome this were dif-
ferent combination and augmentation therapies and last but 
not least ECT. With the inclusion of some second-generation 
antipsychotics such as quetiapine and aripiprazole as add-
on treatments to a pre-existing antidepressant treatment, the 
augmentation strategies were enriched. But nevertheless, 
there is need for other innovative solutions. In the recent 
years, the infusion therapy with ketamine, an antagonist at 
the NMDA-receptor, in depression gave striking results: an 
immediate resolution of the depressive symptoms, includ-
ing suicidality. Recently, this off-label use of the anes-
thetic Ketamine was completed by the license authorisa-
tion of an intranasal spray of Esketamine in the indication 
of therapy-resistant depression (defined by a sequence of 
unsuccessful treatment with two different antidepressants). 
After the positive decision of the FDA EMA followed some 
weeks ago. Thus, we will have this innovative approach 
soon available on the European market. This gives hope 
for an improved depression treatment and raises expecta-
tions that the prevalence of therapy refractory depression 
(defined by no response even after augmentations strategies, 
etc.) in consequence might be reduced and/or that even for 
these patients, Esketamine will be evaluated with a posi-
tive outcome. Although Ketamine/Esketamine is not a new 
compound, the goal-oriented development of this anti-glu-
tamatergic approach, enables the use of a new pharmaco-
logical mechanism for depression treatment. This innovative 
development hopefully opens the doors for other compounds 
with the same or similar mechanism. Unfortunately, the glu-
tamatergic approach in treatment-resistant schizophrenia, in 
case of the glycine reuptake inhibitor, Bitopertin preferen-
tially oriented towards negative symptoms, was not success-
ful (Möller et al. [7], as generally the whole glutamater-
gic approach (among others with compounds such as e.g., 
metabotropic glutamate receptor agonists) in schizophrenia, 
which demonstrated no or only low efficacy.
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